ONTX Insider Trading Activity and SEC Form 4 Filings
ONTX insider trading summary
No open-market insider purchases or sales of Onconova Therapeutics, Inc. (ONTX) have been reported on SEC Form 4 in the past 12 months.
Latest ONTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 28, 2022 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Buy | $3K (1,500 @ $1.67) |
| Jan 21, 2022 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Buy | $3K (1,500 @ $2.02) |
| Jan 14, 2022 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Buy | $3K (1,500 @ $2.20) |
| Jan 7, 2022 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Buy | $4K (1,500 @ $2.39) |
| Nov 19, 2021 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Buy | $3K (1,000 @ $3.16) |
| Sep 28, 2021 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Buy | $10K (2,381 @ $4.20) |
| Sep 28, 2021 | Steven M Fruchtman | President, Chief Executive Off | Buy | $10K (2,381 @ $4.20) |
| Sep 28, 2021 | James J Marino | Director | Buy | $25K (5,952 @ $4.20) |
| Sep 28, 2021 | Mark S. MD Gelder | Chief Medical Officer | Buy | $10K (2,381 @ $4.20) |
| Feb 16, 2021 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Buy | $12K (12,000 @ $1.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.